Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

UK Approves Novo Nordisk's Oral Wegovy for Weight Management

Novo Nordisk's Wegovy® pill (semaglutide tablets) has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), making it the first daily oral GLP-1 treatment for weight management in the UK. The approval is based on the OASIS 4 Phase 3 trial, which showed adults with obesity or overweight achieved an average weight loss of 13.6% with semaglutide 25 mg, compared to 2.4% with placebo, after 64 weeks, alongside lifestyle modifications. This offers an alternative to injectable treatments for eligible adults living with obesity or overweight with at least one weight-related condition.

• The MHRA approval positions Wegovy® pill as the UK's first daily oral GLP-1 treatment for weight management. It is indicated for adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2 to <30 kg/m2) who also have at least one weight-related condition, serving as an adjunct to a reduced-calorie diet and increased physical activity.
• Clinical efficacy was demonstrated in the OASIS 4 trial, where semaglutide tablets 25 mg led to significant weight loss. Participants experienced a 13.6% weight reduction versus 2.4% with placebo over 64 weeks in a treatment policy analysis. An on-treatment analysis showed even greater efficacy, with 16.6% weight loss for semaglutide compared to 2.7% for placebo.
• The safety profile of oral semaglutide 25 mg was consistent with the GLP-1 receptor agonist class, with gastrointestinal side effects like nausea, vomiting, and diarrhoea being the most common, generally mild to moderate and transient. Adverse events leading to treatment discontinuation occurred in 6.9% of participants receiving oral semaglutide, consistent with injectable semaglutide trials. The UK is the third country to approve Wegovy® pill, following the U.S. FDA and the UAE.

Addressing Unmet Needs with UK's First Oral GLP-1 for Obesity

Current obesity treatment approaches face significant challenges across multiple domains, from poor long-term efficacy to systemic barriers that limit patient access to care. These limitations underscore the complexity of obesity as a chronic condition requiring sustained, multifaceted management strategies. The disappointing outcomes with traditional approaches have highlighted the urgent need for more effective therapeutic options.

• Poor long-term treatment outcomes: Most patients are unsuccessful at maintaining durable weight reduction, with recidivism being common despite lifestyle modifications including weight loss programs and exercise interventions

• Limited efficacy of lifestyle interventions alone: For many patients, lifestyle intervention is insufficient to achieve long-term weight loss, with traditional dietary management based on eating pattern modifications, increased physical activity, and psychological support providing inconsistent and disappointing results

• Pharmacotherapy access and sustainability barriers: Four major challenges include determining appropriate prescribing healthcare providers, the necessity for lifelong treatment to sustain benefits, inconsistent third-party reimbursement limiting patient access, and drug shortages compounded by high demand

• Healthcare provider limitations: Health professionals are poorly prepared to address obesity, with biases and unfounded assumptions about patients, absence of training in behavior-change strategies, and limited experience working within interprofessional teams

• Limited pediatric treatment options: Few therapeutic options, few published treatment reports, and no large randomized trials are available for pediatric patients with obesity

• Inadequate pharmacological diversity: Obesity pharmacotherapy has been limited for long-term management due to past failures of several agents, few presently available options, and general utilization as monotherapy rather than combination approaches

• Failure to address root causes: Pharmacological interventions do not address fundamental obesity drivers such as socio-environmental factors influencing food choices, over-reliance on high-calorie processed foods, sedentary lifestyles, and socio-economic disparities

• Implementation gaps: A substantial gap exists between scientific evidence and clinical practice implementation for effective obesity management, requiring barrier addressing at multiple levels including clinician, community, system, and policy domains

OASIS 4: Efficacy and Safety of Oral Semaglutide in Obesity

Recent clinical studies have demonstrated significant advances in obesity treatment, with several large-scale trials evaluating novel interventions and established therapies. These studies encompass diverse populations, including patients with weight-related comorbidities, and provide comprehensive data on both efficacy and safety outcomes. The evidence spans from novel GLP-1 receptor agonists to established interventions, offering insights into comparative effectiveness and optimal treatment approaches.

• SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4 trials (2019-2023) evaluated tirzepatide at varying doses (5 mg, 15 mg, and maximum tolerated dose) in participants with overweight or obesity, including those taking weight-inducing medications. Efficacy outcomes showed mean percentage weight changes ranging from -13.3% to -21.3% in SURMOUNT-1, -26.1% in SURMOUNT-3, and -18.6% in SURMOUNT-4, with weight loss comparable to primary study results even in participants requiring weight-inducing medications.

• LIGHT 1 trial (2024) investigated efsubaglutide alfa, a novel long-acting GLP-1 receptor agonist, in 50 overweight and obese individuals through once-weekly subcutaneous injections across five dose cohorts (5-20 mg). The intervention achieved mean weight reduction of 7.16% versus 0.86% with placebo, with 82.5% of treated participants achieving ≥5% weight loss compared to 0% with placebo, while gastrointestinal adverse events were most common but predominantly mild to moderate.

• Liraglutide Cochrane Review (2025) analyzed 24 RCTs involving 9,937 participants with obesity and weight-related comorbidities including diabetes and cardiovascular conditions. Medium-term outcomes (26-68 weeks) demonstrated percentage weight change of -4.72% and doubled the likelihood of achieving ≥5% weight reduction (RR 2.10), though associated with increased adverse events leading to withdrawal (RR 1.98) and potential increases in serious adverse events (RR 1.20).

• Network meta-analysis comparing tirzepatide and semaglutide (2026) encompassed 28 RCTs with 34,367 participants, showing tirzepatide's superiority over semaglutide in percentage weight reduction (mean difference 6.10%), absolute weight loss (4.55 kg), BMI reduction (1.71 kg/m²), and glycemic control with HbA1c reduction of 0.33% and fasting glucose reduction of 10.39 mg/dL.

• ESG versus Liraglutide comparative study (2025) enrolled 43 patients with class I and II obesity, comparing endoscopic sleeve gastroplasty (ESG, n=23) with liraglutide treatment (n=20) over 12 months. ESG demonstrated greater initial weight loss at 3 and 6 months, while liraglutide showed slower but more consistent weight loss continuing after six months, with no major complications or significant side effects reported in either group.

Wegovy Pill's Role in the Evolving UK Obesity Treatment Landscape

The obesity treatment landscape has undergone significant transformation over the past five years, driven primarily by the emergence of highly effective GLP-1 receptor agonists and dual/triple hormone receptor agonists. Recent approvals include semaglutide and tirzepatide, which have demonstrated superior weight loss efficacy compared to earlier generation anti-obesity medications. Tirzepatide, a GIPR/GLP-1R co-agonist, received Fast Track designation for obesity management following its diabetes approval, with combined receptor agonism appearing to induce fewer side effects than single-pathway approaches. Novel oral GLP-1 receptor agonists like orforglipron have shown promise, with the 36 mg dose achieving mean body weight reduction of 11.2% over 72 weeks, with 54.6% of patients achieving ≥10% weight loss compared to 12.9% with placebo.

Despite these therapeutic advances, real-world utilization remains disappointingly low, with only 1.8% of eligible adults initiating newer anti-obesity medications among nearly 320,000 eligible patients in recent studies. Semaglutide accounts for 77.9% of initiations, followed by tirzepatide at 19.7% and liraglutide at 17.8%. Significant disparities persist in treatment access, with reduced odds of initiation observed among Black and Hispanic populations compared to White patients, and substantially lower utilization among Medicaid and uninsured patients versus those with private insurance. The treatment landscape also reveals concerning patterns of medication discontinuation, with average monthly weight regain of 0.4 kg following cessation, and all cardiometabolic benefits projected to return to baseline within 1.4 years after stopping treatment.

The evolving clinical evidence has prompted updated treatment recommendations emphasizing obesity as a chronic, progressive disease requiring comprehensive, long-term management. Strong recommendations now support the use of semaglutide, tirzepatide, and combination naltrexone-bupropion, with conditional recommendations extending to specific obesity-related complications including obstructive sleep apnea, heart failure with preserved ejection fraction, and metabolic dysfunction-associated liver disease. Real-world effectiveness studies demonstrate that patients achieving optimal outcomes typically require median attempts with three unique weight management strategies before successful treatment initiation, with 88% reporting positive experiences on current medications, particularly those maintaining therapy for six months or longer.

UK Approval: Oral Semaglutide's Impact on Obesity Care

The recent UK approval of oral semaglutide for weight management represents a significant evolution in how obesity, a complex and chronic disease, can be addressed. For many individuals, the prospect of daily or weekly injections has been a considerable barrier to initiating or maintaining effective anti-obesity medication. This new oral formulation directly tackles that challenge, potentially unlocking treatment for a broader patient population and fostering greater adherence to long-term therapy. Clinical trials have consistently demonstrated the profound efficacy of semaglutide in achieving substantial weight loss, often exceeding 13-15%, which is a game-changer compared to older anti-obesity medications. Beyond weight reduction, GLP-1 receptor agonists like semaglutide also offer benefits in glycemic control and cardiometabolic health, particularly for those with type 2 diabetes or high cardiovascular risk. This expanded therapeutic option allows healthcare providers to tailor treatment more effectively to individual patient preferences, integrating pharmacotherapy into a holistic management plan that still emphasizes lifestyle modifications. However, the enthusiasm for this advancement must be tempered with a realistic understanding of the challenges. The high cost of GLP-1RAs remains a significant hurdle, contributing to access disparities and potentially limiting equitable uptake, especially for lower-income individuals. Furthermore, while effective during treatment, studies indicate that weight regain is common upon discontinuation, underscoring the need for sustained, potentially lifelong, therapy. Managing common gastrointestinal side effects also requires careful patient support and guidance to ensure tolerability and persistence. As the anti-obesity medication market continues to innovate with dual and tri-agonists, the availability of an effective oral GLP-1RA sets a new benchmark, but its true impact will depend on addressing these critical access, adherence, and support considerations.